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S290 Poster Session IIwas observed in mice receiving a single dose of silica (3mg silica/
mouse IV) one day prior to GVHD induction as compared to mice
receiving Tcon only (77 days vs. 29 days, respectively, P 5
0.0164). This result correlated with a decrease in Tcon proliferation
as illustrated by whole body bioluminescence imaging (BLI) as well
as ex vivo imaging of lymph nodes, spleen and gastrointestinal tract.
This decrease in T con proliferation was confirmed with CFSE-la-
beled Tcon re-isolated on day 5 after BMT, with 50% of CD4+ T
cells proliferated in the pLN of control mice, yet only 30% prolifer-
ated in silica treated mice (30%, P 5 0.0004). The spleen showed
more proliferation of CD4+ T cells overall, however there was still
a significantly less proliferation in mice receiving silica than in con-
trol mice (79% and 95%, respectively, P5 0.0023). In addition, silica
treatment resulted in less overall inflammation as indicated by anal-
ysis of serum cytokine levels. In particular, significantly less IFNg,
TNF-a, IL-2, IL-4, IL-5,GM-CSF, IL-10, and IL-12were detected
in the serum from mice treated with silica than from control mice.
Together, these results suggest that silica-induced impairment of
macrophage function results in reducedT con proliferation, reduced
inflammation, and prolonged survival after GVHD induction.377
OPTIMIZATION OF ANTI-THYMOCYTE GLOBULIN EXPOSURE IN PAEDI-
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Background: Hematopoietic stem cell transplantation (HSCT) is
complicated by severe infectious complications during the lympho-
penic period after HSCT, which increases mortality and morbidity.
Anti-thymocyte globuline (ATG) is administered prior to allogeneic
HSCT to reduce risks of graft-rejection and graft versus host
(GvHD). Large interpatient variations in pharmacokinetics (PK) of
ATG have been reported, possibly due to differences in bodysize,
cell numbers prior to ATG, ‘‘the given graft’’, and other patient
characteristics.
Currently, all patients receive the same dose based on bodyweight.
This non-individualized dosage is likely to either increases the risk of
GvHD (by under dosing) or delays post-tranplant immune reconsti-
tution (by overdosing). This study aims to explain the relation
between the above mentioned patient and HSCT related character-
istics and the pharmacokinetics of ATG as a basis to design an
individualized dosing regimen.
Methods: 142 patients, ranging between 4.5 and 80 kg body weight,
who received HSCT between 2004 and 2009 in the two Dutch pedi-
atric hospitals were included. 72 patients received bone marrow, 48
cord blood and 22 peripheral stem cell transplants, containing 23 to
110 CD34+cells. A median dose of rabbit ATG (Imtix) of 10mg/kg
was given in consecutive 4 days. The level of active ATG capable
of binding to T lymphocytes (HUT 78) was measured by quantita-
tive flow cytometry (FACS), total ATG by ELISA. PK analysis was
performed using NONMEM.
Results: Large interindividual variability was observed in PK of
ATG. Preliminary results of the pharmacokinetic model of active
ATG showed a linear relationship between body weight and clear-
ance in children under approximately 20 kg body weight. In children
over 20 kg large variability was observed, which could not be ex-
plained by bodyweight. In 15 Patients, who produced IGG-
antibodies against ATG a more rapid clearance was observed in
comparison with patients who did not form antibodies.
Conclusions: The results of the pharmacokinetic model show that
a fixed dose of 10 mg/kg in all pediatric patients does not lead to
the same exposure of active ATG in all patients ranging 1 month
and 21 years of age. Optimization of the pharmacokinetic will be per-
formed in order to derive a paradigm for individualized dosing, lead-
ing to a more predictable exposure in all patients.378
INCIDENCE AND OUTCOME OF ADENOVIRUS INFECTION IN ADULT AL-
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Background:True adenovirus infection, but has been reported in 5-
20% of allogeneic hematopoietic stem cell transplant (allo HCT) re-
cipients, with\2% of patients developing severe adenoviral disease.
Adenovirus infection is generally associated with profound immuno-
suppression and a poor outcome. We evaluated the incidence and
significance of adenovirus detection among allo HCT recipients at
our institution between 1999 and 2009.
Methods: Viral culture was used to isolate adenovirus from various
sterile and non-sterile sources. An immunofluorescence assay was
used for confirmation. Definitive infection was the isolation of ade-
novirus from a sterile source with tissue invasion and compatible
clinical presentation. Probable infection represented isolation of
the virus from a non-sterile source without tissue data but with
compatible clinical features. Disseminated disease was defined as
the involvement of . 2 organs.
Results: Seventy-five patientswith at least onepositive adenovirus cul-
ture, representing 1.4%of all alloHCT recipients during the study pe-
riod,were identified.Transplant typeswerematched related (36; 48%),
matched unrelated (22; 29%), haploidentical (9; 12%), and umbilical
cord blood (8; 10%). At the time of adenovirus infection, acute (gra-
deII-IV) or chronic graft versus host disease (GVHD) was present in
18 (24%) and 30 patients (40%), respectively. Sixty-nine of these pa-
tients had probable adenovirus infection while 6 had definitive infec-
tion. Thirteen patients (17%) had disseminated disease. Median time
from allo HCT to adenovirus infection was 4.8 months (range 0.3 to
80).Eightpatients (10%) receivedanti-adenovirus treatmentwithcido-
fovir. The most common clinical manifestations were pneumonia (20,
27%),hemorrhagiccystitis (13,17%),upper respiratory tract infections
(12,16%),andenteritis (11,15%).Medianoverall survivalwas5months
and the 2-year survival was 33%. The presence of acute GVHD (p5
0.001), treatment with methylprednisolone (p5 0.0003) and dissemi-
nated adenovirus disease (p5 0.02) were associatedwith a significantly
shorter overall survival. In contrast, the type of allo HCT, use of cido-
fovir, ATG, or probable vs. definitive adenovirus infection did not have
a significant impact on survival.
Conclusions: Adenovirus infection is relatively uncommon after
allo HCT. Dissemination of adenovirus is associated with a signifi-
cantly poor outcome in patients with acute GVHD and systemic
use of steroids.379
KL-6 AS A MARKER FOR BRONCHIOLITIS OBLITERANS IN PEDIATRIC
AND YOUNG ADULT BONE MARROW TRANSPLANT PATIENTS
Flatt, T., Neville, K., Dalal, J. Children’s Mercy Hospital, Kansas City,
MO
Background: Bronchiolitis obliterans syndrome (BOS) is a serious
complication of allogeneic bone marrow transplant (BMT). There
is a need for a non-invasive diagnostic test in order to detect BOS
in transplant recipients. KL-6 is a high molecular weight glycopro-
tein classified asMUC1mucin that is expressed on the epithelial sur-
face of type II alveolar cells in the lungs and is present on the surface of
bronchiolar epithelial cells. KL-6 is an active chemotactic factor for
fibroblasts which could play a role in the early pathogenesis of BOS.
Objective:We hypothesize that serum KL-6 levels will be elevated
in subjects with known BOS.
StudyDesign:This is a case control study that employs convenience
sampling for KL-6 samples. It is a multi-center study.
Methods: Serum samples were obtained from 15 subjects that un-
derwent allogeneic BMT and 20 healthy controls between the ages
of 6 months and 30 years. Of the 15 subjects that underwent
BMT, 3 met the criteria for BOS. The definition of BOS was based
upon pulmonary function tests (a sustained drop in FEV1 of 20%
from pre-transplantation baseline) or biopsy. KL-6 levels were
Poster Session II S291determined using a commercially available sandwich-type enzyme
linked immunosorbent assay kit.
Results:MeanserumKL-6 levels+/2 standarddeviation forBMTsub-
jects with BOS, BMT subjects without BOS and healthy controls were
571.6 +/2350.5, 302.3 +/287.3 and 209.1 +/277.6 U/ml, respectively.
The difference between BMT subjects with BOS and those without
BOS was statistically significant (p 5 0.003) as well as those with BOS
and healthy controls (p 5 0.001). There was no statistical difference
between BMT subjects without BOS and healthy controls (p5 .956).
Conclusions: KL-6 levels were significantly elevated in BMT sub-
jects with BOS as compared those without BOS and healthy controls.
KL-6 could serve as a diagnostic tool in detecting BOS in BMT
recipients.Table 1. Phase II Trial Clinical Outcomes
Clinical Outcome Incidence
Confidence
Interval
Cumulative Incidence of Grade II-IV aGVHD 13% (0.05-0.25)
Cumulative incidence of death without grade
II-IV aGVHD before day 100
13% (0.05-0.250)
Overall non relapse mortality 26% (0.16-0.41)
cGVHD 28% (0.17-0.43)
Relapse 17% (0.09-0.31)
TTP 4.4% (0.03-0.2)
CMV PCR 31% (0.19-0.45)
EBV PCR 20% (0.1-0.33)
HSV stomatitis & BK cystitis* 13% (0.06-0.26)
Bacterial infections 60% (0.45-0.73)
Oral candidiasis 6.7% (0.02-0.17)
SOS 6.7% (0.02-0.17)
*This incidence is for each of the the two viral infections.380
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION VERSUS BONE
MARROW TRANSPLANTATION IN SEVERE APLASTIC ANEMIA
Ghavamzadeh, A., Alimoghaddam, K., Hamidieh, A.A., Jalili, M.,
Bahar, B., Iravani, M., Mousavi, S.A., Jahani, M. Tehran University
of Medical Sciences, Tehran, Islamic Republic of Iran
Introduction: Severe Aplastic Anemia (SAA) is a rare disease and the
outcome of these patients has improved with hematopoietic stem cell
transplantation (HSCT). In patients who have anHLA-identical sib-
ling donor, HSCT is the preferred treatment. This is a retrospec-
tively study in patients who received bone marrow (BMT) or
peripheral blood stem cell transplantation (PBSCT) and compared
the differences in hematologic recovery, acute and chronic
GVHD, relapse and disease free survival and overall survival in
two groups.
Methods: Totally 173 patients with diagnosis of SAA between
March 1991 and October 2010, received allogeneic hematopoietic
stem cell transplantation from an HLA-identical sibling donor (167
patients) orHLA fullmatched other related donor (6 patients).Three
patients exclude from study because received both bone marrow and
peripheral blood.Median age in BMTgroup was 17 years (range 1 to
32 year) and in PBSCTwas 23 years (range 2 to 50 year). All patients
received the conditioning regimencontaining cyclophosphamide and
ATG as our center protocol and cyclosporine and methotrexate for
graft-versus-host disease (GVHD) prophylaxis.
Result: The median of follow-up was 40 and 20.5 month in BMT
and PBSCT group respectively. The median time to reach ANC $
500/mm3 and platelet $ 20000/ml in PBSCT group (11 and 17
days, respectively) was significantly lower than BMT group (16
and 19 days, respectively) (P\ 0.001). In two groups there was no
difference in the incidence of acute GVHD (p 5 1.0). The cumula-
tive incidence of chronic GVHD for those who survived more than
90 days was 10.2% in the BMT group, compared to 27% in the
PBSCT group (p 5 0.022). Relapse of disease occur in twelve
(24%) patients among BMT recipients and in 8 (6.5%) patients of
PBSCT recipients (p 5 0.005). Disease-free survival at 1 year was
74% in the BMT group and 86% in the PBSCT group (p 5 0.24)
and Overall survival at 1 year was 82% in the BMT group and
89% in the PBSCT group (p 5 0.8). Nine patients in BMT group
and 19 patients in PBSCT group were dead.
Discussion:However it seems that bone marrow is preferred source
for progenitor cell for SAA transplantation but this study results
showed that there was no difference in overall survival and disease
free survival in two groups. But engraftment was rapid in multi-
transfused patients who undergoing PBSCT than BMT with
significant differences.381
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Background: Acute graft versus host disease continues to affect ap-
proximately 60% of patients undergoing UHSCT, with significant
mortality and morbidity.
Methods: We prospectively evaluated the efficacy of combining
Thymo (4.5 mg/kg divided doses on days -1,-2, and -3), Tacrolimus
and Sirolimus in preventing aGVHD. The cumulative incidence rate
at 100 days of grade II-IV aGVHDwas calculated using death without
grade II-IV aGVHD as competing risk. The median time to relapse,
defined as time from BMT to the event of relapse or death due to re-
lapse, was reported using KM method. The proportions of relapse,
non-relapse mortality, cGVHD, and incidence of infections were re-
ported with the Wilson’s 95% Confidence Interval (in table below).
Results: Between August 2008 and August of 2010, 45 patients (pts)
were enrolled, with median age of 53(20-70) years. The Median fol-
low-up time is 10.5 months (1.3-26.5). There were 20 AML, 11
MDS, 4 ALL, 2 CML, 1 CLL, 3 Myelofibrosis, 2 multiple myeloma,
2 NHL pts. Preparative regimens included Bu/Flu (29), Bu/Flu-TBI
(9), VP16/TBI (3), R-BEAM (1), and Flu/MEL-TBI (3). All pts re-
ceived peripheral blood stem cells mobilized with G-CSF. Median
CD34+ dose was 7.31x106 /kg (1.9-18.6). Twenty pts received 8/8
and 25 received 7/8HLAmatched grafts respectively. All patients’ en-
grafted,withmediandayof 12 (9-18).Sixteendeaths occurred through-
out the entire follow up period, due to: relapse (4), aGVHD (2),
cGVHD (3), sinusoidal obstruction syndrome (SOS) (1), bleeding
(1), multi organ failure (2), sepsis (2) and pneumonia (1). Eight patients
experienceddisease relapse.Twelvepatientshadnon-relapsemortality.
Thirteen pts developed aGVHD, 7 grade I, 3 grade II, 2 grade III,
and 1 grade IV. The cumulative incidence rate for grade II-IV
aGVHD at 100 days is 0.13 (0.053, 0.250); the cumulative incidence
rate of the competing event death without grade II-IV aGVHD at
day 100 is 0.13 (0.053, 0.250). Thirteen pts developed cGVHD.
There were 2 cases of thrombotic thrombocytopenic purpura
(TTP) before day 100. 14CMVby PCR, 9 EBV by PCR, 6HSV sto-
matitis, 6 BK cystitis, 27 bacterial infection, 3 oral candidiasis, and 3
SOS. The median time to relapse was 18.38 months.Conclusion: These early results suggest that the combination of
Thymo, Tacrolimus and Sirolimus in pts undergoing UHSCT is
well tolerated and is associated with a low rate and severity of acute
GVHD. Six months follow up data will be presented at the meeting.
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EFFECT OF RELATED AND UNRELATED DONOR HAEMATOPOIETIC STEM-
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HEMATOLOGICAL DISEASE: AN INTENTION-TO-TREAT ANALYSIS OF
410 PATIENTS AT A SINGLE CENTER INSTITUTION
Lupo-Stanghellini, M.T.1, Forno, B.1, Marcatti, M.1, Bitetti, C.1,
Coppola, M.1, Assanelli, A.1, Greco, R.1, Lunghi, F.1, Tassara, M.1,
